Gilead Sciences Holds Annual Meeting, Elects Directors

Ticker: GILD · Form: 8-K · Filed: 2024-05-09T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, annual-meeting, auditor

Related Tickers: GILD

TL;DR

Gilead shareholders re-elected all directors and approved the auditor at the annual meeting.

AI Summary

On May 8, 2024, Gilead Sciences, Inc. filed an 8-K report detailing several key events. The company announced the results of its annual meeting of stockholders, where all nominated directors were elected and a proposal to ratify the appointment of PricewaterhouseCoopers LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2024, was approved. Additionally, the company filed amendments to its bylaws.

Why It Matters

The election of directors and ratification of the auditor are routine but essential corporate governance actions that provide stability and oversight for Gilead Sciences.

Risk Assessment

Risk Level: low — This filing concerns routine corporate governance matters and does not indicate any significant new risks or changes in the company's financial or operational status.

Key Players & Entities

FAQ

Were all nominated directors elected at the annual meeting?

Yes, all nominated directors were elected at the annual meeting of stockholders held on May 8, 2024.

What was the outcome of the proposal to ratify the appointment of the independent registered public accounting firm?

The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was approved by the stockholders.

What is the company's principal executive office address?

The address of the principal executive offices is 333 Lakeside Drive, Foster City, California 94404.

What is the state of incorporation for Gilead Sciences, Inc.?

Gilead Sciences, Inc. is incorporated in Delaware.

What is the filing date of this Current Report on Form 8-K?

The filing date of this Current Report on Form 8-K is May 9, 2024, with the earliest event reported being May 8, 2024.

From the Filing

0000882095-24-000016.txt : 20240509 0000882095-24-000016.hdr.sgml : 20240509 20240509161100 ACCESSION NUMBER: 0000882095-24-000016 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240508 ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240509 DATE AS OF CHANGE: 20240509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GILEAD SCIENCES, INC. CENTRAL INDEX KEY: 0000882095 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943047598 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19731 FILM NUMBER: 24930688 BUSINESS ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6505743000 MAIL ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: GILEAD SCIENCES INC DATE OF NAME CHANGE: 19930328 8-K 1 gild-20240508.htm FORM 8-K gild-20240508 0000882095 12/31 false 0000882095 2024-05-08 2024-05-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 8, 2024 GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission File No.) (IRS Employer Identification No.) 333 Lakeside Drive , Foster City , California (Address of principal executive offices) 94404 (Zip Code) 650 - 574-3000 (Registrant’s Telephone Number, Including Area Code) Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12 ☐      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value, $0.001 per share GILD The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ Item 5.03      Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year. On February 1, 2024, the Board of Directors (the “Board”) of Gilead Sciences, Inc. (the “Company”) adopted amendments to the Company’s Restated Certificate of Incorporation (the “Amendment”) to reflect new Delaware law provisions regarding officer exculpation under Section 102(b)(7) of the Delaware General Corporation Law (the “DGCL”). On May 8, 2024 , the Company’s stockholders approved the Amendment at the Company’s

View on Read The Filing